6 Top Gainers In Healthcare Sector (AKAO, CRON, GMDA...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Achaogen Inc. (AKAO)

Gained 17.39% to close Monday's (Jan.28) trading at $1.62.

News: No news

Recent events:

-- On November 5, 2018, the Company announced a review of strategic alternatives to maximize shareholder value and restructuring to preserve cash resources and reduce total expenses. -- On October 15, 2018, the Company announced the submission of a Marketing Authorization Application to the European Medicines Agency for Plazomicin seeking approval Complicated urinary tract infections (cUTI), including pyelonephritis; bloodstream infections (BSI) due to certain Enterobacteriaceae; and Infections due to Enterobacteriaceae in adult patients with limited treatment options.

Plazomicin, under brand name Zemdri, received FDA approval last June for the treatment of complicated urinary tract infections.

2. MYnd Analytics Inc. (MYND)

MYnd is a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients.

Gained 16.90% to close Monday's trading at $1.66.

News: No news

On January 7, the Company announced that it has entered into a definitive stock-for-stock merger agreement with Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment.

Emmaus is a commercial stage biopharmaceutical company, and its lead FDA-approved product is Endari, which is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Following the merger, Emmaus will become a wholly owned subsidiary of MYnd Analytics in exchange for MYnd Analytics' issuance of common stock to Emmaus shareholders and other equity holders. The surviving company will change its name to Emmaus and receive a new ticker symbol to reflect the name change.

The merger transaction is subject to the approval of shareholder by both companies, and other conditions.

3. Cronos Group Inc. (CRON)

Cronos is a Canadian marijuana company and is the first marijuana company to be listed on the U.S. stock exchange.

Gained 15.36% to close Monday's trading at $18.48.

News: No news

Recent event:

-- On December 7, 2018, the Company announced a C$2.4 billion equity investment from Altria Group, Inc. (MO).

Altria has agreed to make Cronos Group its exclusive partner for pursuing cannabis opportunities throughout the world subject to certain limited exceptions. The transaction is expected to close in the first half of 2019.

4. Gamida Cell Ltd. (GMDA)

Gained 13.68% to close Monday's trading at $12.96.

News: No news

Near-term Catalysts:

-- New data from the ongoing phase I study of NAM-NK, an investigational, cell-based cancer immunotherapy, in patients with non-Hodgkin lymphoma and multiple myeloma will be presented on February 20, 2019. -- Initial data from a Phase 1/2 study of NiCord in patients with severe aplastic anemia will also be presented on February 20, 2019.

5. Anixa Biosciences Inc. (ANIX)

Gained 11.46% to close Monday's trading at $4.96.

News: No news

Pipeline & Near-term Catalysts:

-- The Company's CAR-T program for solid tumors is expected to advance into clinical testing in the summer of 2019. -- The Company is also developing a blood test for early cancer detection called Cchek.

6. Surface Oncology Inc. (SURF)

Gained 10.53% to close Monday's trading at $5.88.

News: No news

Clinical Trials & Near-term Catalysts:

-- The Company's lead product candidate is SRF373, under phase I trial in patients with advanced solid tumors and hematologic malignancies. This trial was initiated last March. The initial data from this trial is anticipated in the first half of 2019. -- Another phase I trial of SRF373 as a single agent and in combination with other cancer immunotherapies was initiated last June.

This compound is being developed under the strategic collaboration with Novartis under which Surface has the option to retain US development and commercial rights.